AptarGroup, Inc. (ATR) Guidance & Earnings Results

On 2026-07-30 AptarGroup, Inc. reaffirmed guidance: "Q3 2026 adjusted EPS $1.45-$1.53; effective tax rate 22.5%-24.5%; EUR/USD…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ATRAptarGroup, Inc.Follow ATR — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 8.0B
P/E TTM: 22.8
Dividend yield: 1.5%
52-week: —
Next earnings: 29 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Reaffirmed	Q3 2026 adjusted EPS $1.45-$1.53; effective tax rate 22.5%-24.5%; EUR/USD 1.14
30 Apr 26	Reaffirmed	Q2 growth expected across segments excluding emergency medicine destocking
5 Feb 26	Mixed	Expects strong growth in Pharma outside emergency medicine, which is destocking
30 Oct 25	Reaffirmed	Pharma pipeline expected to contribute 7-10% revenue annually; injectables growth driven by GLP-1, Annex-1, biologics · full year
31 Jul 25	Reaffirmed	Q3 2025 adj. EPS $1.53-1.61, including $0.06-0.07 higher legal fees for pharma IP litigation. Effective tax rate 20.5%-22.5%.

AptarGroup, Inc. — questions

What guidance did AptarGroup, Inc. give?: On 2026-07-30: "Q3 2026 adjusted EPS $1.45-$1.53; effective tax rate 22.5%-24.5%; EUR/USD 1.14"
When does AptarGroup, Inc. report earnings?: AptarGroup, Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from AptarGroup, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.